Two months after Merck said it would pay Moderna $250 million to co-develop this collaboration, a phase 2b trial found a 44 percent reduction in the risk of recurrence or death in stage 3/4 melanoma patients compared to Keytruda on its own. Serious side effects occurred in 14.4 percent of the combined-therapy group versus 10 percent in Keytruda-only patients.
“Today’s results are highly encouraging for the field of cancer treatment,” Moderna CEO Stéphane Bancel said in a statement. “mRNA has been transformative for COVID-19, and now, for the first time ever, we have demonstrated the potential for mRNA to have an impact on outcomes in a randomized clinical trial in melanoma.”
A phase 3 trial to further test the mRNA-based technology and Keytruda among patients with skin cancer is planned to start in 2023, according to the drugmakers.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
